Who Owns Enliven Therapeutics Stock?
NASDAQ: ELVNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 116.09%
- Institutions (% of float)
- 123.75%
- Held by insiders
- 6.19%
- Institutional holders
- 307
- Institutions 93.8%
- Insiders 6.2%
- Public and other 0.0%
Who owns Enliven Therapeutics stock?
Institutional investors own about 116.1% of Enliven Therapeutics's shares, spread across 307 institutions that file 13F reports. That level of institutional ownership is high, typical of large, widely followed companies. Insiders, including executives, directors and large founding shareholders, hold 6.19% of ELVN.
The largest institutional holders are FMR, LLC (14.71%), Orbimed Advisors LLC. (9.21%) and Polar Capital Holdings PLC (8.73%). Together, the top 10 institutions control 61.2% of shares outstanding. In their latest filings, 4 of the top 10 institutions increased their ELVN positions and 3 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of ELVN
| Institution | Shares | % Held | Change |
|---|---|---|---|
| FMR, LLC | 10.83M | 14.71% | +8.0% |
| Orbimed Advisors LLC. | 6.78M | 9.21% | 0.0% |
| Polar Capital Holdings PLC | 6.43M | 8.73% | -0.1% |
| Blackrock Inc. | 5.71M | 7.76% | +31.0% |
| Commodore Capital Lp | 3.27M | 4.45% | 0.0% |
| Vestal Point Capital, LP | 3.23M | 4.38% | -19.4% |
| Vanguard Capital Management LLC | 2.89M | 3.93% | +12.6% |
| Price (T.Rowe) Associates Inc | 2.35M | 3.19% | -19.1% |
| Fairmount Funds Management LLC | 1.86M | 2.52% | 0.0% |
| Geode Capital Management, LLC | 1.71M | 2.32% | +21.4% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of ELVN
| Fund | Shares | % Held |
|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.88M | 2.56% |
| iShares Trust-iShares Russell 2000 ETF | 1.51M | 2.05% |
| Fidelity Select Portfolios-Select Health Care Portfolio | 1.28M | 1.74% |
| Fidelity Securities Fund-Fidelity Small Cap Growth Fund | 1.25M | 1.70% |
| Fidelity Rutland Square TRT II-Strategic Advisers Fidelity U.S. Total | 1.12M | 1.53% |
| T. Rowe Price New Horizons Fund, Inc. | 807.33K | 1.10% |
| Fidelity Capital Trust-Fidelity Stock Selector Small Cap Fund | 704.26K | 0.96% |
| Fidelity Securities Fund-Fidelity Small Cap Growth K6 Fund | 648.11K | 0.88% |
| T. Rowe Price Health Sciences Fund, Inc. | 647.45K | 0.88% |
| Fidelity Advisor Series VII-Fidelity Advisor Health Care Fund | 630.00K | 0.86% |
Frequently asked questions
Who is the largest shareholder of Enliven Therapeutics?
FMR, LLC is the largest institutional shareholder of ELVN, owning 14.71% of shares outstanding (10.83M shares) as of its latest 13F filing.
What percentage of Enliven Therapeutics is owned by institutions?
Institutions own about 116.1% of ELVN shares and 123.8% of the public float.
How much of Enliven Therapeutics do insiders own?
Insiders, such as officers and directors, own about 6.19% of ELVN shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.